• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does CareCredit Integration Change The Bull Case For Synchrony Financial Stock?

    Simply Wall St·10/19/2026 05:28:55
    Listen to the news
    • Weave recently launched a live integration with Synchrony Financial's CareCredit, giving healthcare front desks real-time access to patient financing options within Weave's workflow and enabling mobile and text-to-pay experiences.
    • The integration moves CareCredit from a separate portal into everyday practice operations, which can influence how often patients choose financing and how deeply Synchrony embeds into healthcare software platforms.
    • We will look at how Synchrony Financial's investment narrative intersects with this CareCredit software integration as earnings expectations converge.

    Scan beyond Synchrony Financial and this CareCredit partnership by checking a curated group of healthcare focused lenders and payment players inside the list of solid balance sheet and fundamentals (25 results).

    Synchrony Financial Investment Narrative Recap

    To own Synchrony Financial, you need to be comfortable with a consumer lender that leans heavily on partner ecosystems, digital payments and embedded finance, while dealing with earnings that analysts currently expect to decline 2.7% a year over the next three years. The near term swing factor sits in upcoming results, where the firm has previously missed revenue expectations and is now anticipated to post flat sales year on year.

    The biggest operational risk is straightforward: revenue or net interest margin shortfalls persisting while operating costs stay elevated, after other expense reached US$1.3b and lifted the efficiency ratio to 35.8%. The new Weave CareCredit tie up likely does not move those near term numbers materially, but it does indicate where management is trying to grow.

    The Weave integration is the clearest operational read through for Synchrony Financial around this news. CareCredit is already one of the firm’s key health and wellness platforms, and integrating it directly into front desk software puts Synchrony’s financing options closer to the point of decision. This can matter when revenue expectations are muted and analysts see earnings drifting lower.

    What stands out is execution risk. Synchrony is investing in AI, data and embedded finance, from CareCredit software integrations to Stripe and Walmart OnePay, at the same time analysts expect earnings to contract and revenue to expand 12% a year. Your judgment call is whether integrations like Weave, combined with a 20.8% return on equity and a low 7x P/E, are enough to offset high bad loans of 2% and recent share price underperformance year to date.

    Synchrony Financial's narrative projects US$16.8b revenue and US$3.1b earnings by 2029. This assumes 19.1% yearly revenue growth and an earnings decline of US$0.3b from US$3.4b today.

    Uncover how Synchrony Financial's fair value indicates a 21% potential upside to its current price before the market closes that discount.

    NYSE:SYF 1-Year Stock Price Chart
    NYSE:SYF 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest Synchrony Financial forecasts lean hard into revenue pressure as the key risk. Those analysts were pencilling in about US$17.6b of revenue and only US$2.7b of earnings by 2029, which is well below consensus. The new Weave CareCredit integration could eventually nudge those views, so use it as a prompt to compare multiple narratives yourself.

    Explore 4 other Synchrony Financial fair value estimates, including one that suggests it could be worth just $87.88.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Synchrony Financial?

    If you want to pressure test your view on Synchrony Financial, set it alongside a wider watchlist. Using the Simply Wall St Screener, you can line it up against very different business models and balance sheets, then decide where the risk and reward trade off suits you best.

    • For potential mispriced opportunities with stronger fundamentals than the market might be pricing in, start with a curated set of 33 high quality undervalued stocks that combine quality with more conservative expectations.
    • If resilience matters more to you than rapid expansion, compare Synchrony Financial to a group of 32 resilient stocks with low risk scores that screen well on financial strength and volatility.
    • When you want sturdier income profiles rather than just capital gains, focus on companies in the 8 dividend fortresses that aim for yields above 5% with more robust underlying metrics.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.